Key points from article :
Age-related macular degeneration (AMD) is the most common cause of blindness over age 50.
Gene therapy can be injected in to the eye using a next-generation vector.
Once inside the cells, the DNA sequence begins making the aflibercept protein.
Therefore a single dose will be enough for a very long time.
Phase 1 clinical trial has enrolled 12 patients up to now who received a single injection.
Since entering the trial, patients did not require any rescue treatments through the first six months.
Research by Weill Cornell Medical College in New York City.
